MDGL · Madrigal Pharmaceuticals, Inc.
$546.79
+11.10 (+2.07%)
At close · Jul 21
Market Cap
$12.61B
Shares
23.06M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Bill Sibold | CEO | $19,206,341 |
| David Soergel | Chief Medical Officer | $9,190,678 |
| Rebecca Taub | Chief Medical Officer | $6,868,016 |
| Mardi Dier | CFO | $6,085,089 |
| Carole Huntsman | Executive Vice President and Chief Commercial Officer | $5,441,736 |
| Shannon Kelley | Executive Vice President and Chief Legal Counsel | $5,179,352 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Bill Sibold | CEO | $12,214,250 |
| Mardi Dier | CFO | $8,751,912 |
| Rebecca Taub | Chief Medical Officer | $5,967,206 |
| Shannon Kelley | Executive Vice President and Chief Legal Counsel | $4,673,764 |
| Carole Huntsman | Executive Vice President and Chief Commercial Officer | $3,949,441 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Bill Sibold | CEO | $32,268,400 |
| Paul Friedman | CEO | $9,563,286 |
| Remy Sukhija | Chief Commercial Officer | $7,362,378 |
| Rebecca Taub | Chief Medical Officer | $6,928,008 |
| Brian J. Lynch | General Counsel | $5,266,584 |
| Alex Howarth | CFO | $5,262,023 |
| Carole Huntsman | Executive Vice President and Chief Commercial Officer | $3,142,354 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Paul Friedman | CEO | $5,395,385 |
| Brian J. Lynch | General Counsel | $4,758,149 |
| Rebecca Taub | Chief Medical Officer | $4,664,881 |
| Remy Sukhija | Chief Commercial Officer | $3,510,849 |
| Alex Howarth | CFO | $3,482,906 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Alex Howarth | CFO | $7,131,804 |
| Paul Friedman | CEO | $5,318,389 |
| Rebecca Taub | Chief Medical Officer | $4,610,146 |
| Marc R. Schneebaum | CFO | $3,704,789 |
| Brian J. Lynch | General Counsel | $3,430,481 |
| Remy Sukhija | Chief Commercial Officer | $2,768,467 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Paul Friedman | CEO | $4,535,446 |
| Brian J. Lynch | General Counsel | $4,447,893 |
| Rebecca Taub | Chief Medical Officer | $3,882,343 |
| Remy Sukhija | Chief Commercial Officer | $3,438,902 |
| Marc R. Schneebaum | CFO | $2,940,472 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Paul Friedman | CEO | $6,093,192 |
| Rebecca Taub | Chief Medical Officer | $5,269,843 |
| Brian J. Lynch | General Counsel | $4,068,637 |
| Marc R | CFO | $3,532,652 |
| Marc R. Schneebaum | CFO | $3,532,652 |
Fiscal 2018
| Executive | Role | Total |
|---|---|---|
| Paul Friedman | CEO | $5,628,666 |
| Rebecca Taub | Chief Medical Officer | $4,340,446 |
| Marc R | CFO | $3,366,100 |
| Marc R. Schneebaum | CFO | $3,366,100 |
Fiscal 2017
| Executive | Role | Total |
|---|---|---|
| Paul Friedman | CEO | $1,364,982 |
| Rebecca Taub | Chief Medical Officer | $1,091,795 |
| Marc R | CFO | $970,294 |
Key facts
CIK
1157601
CUSIP
558868105
13F (30d)
37 filings
36 filers
Visit website
Investor relations